The contribution of hematopoietic stem cells to beta-cell replacement

Valeria Sordi, Lorenzo Piemonti

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Hemopoietic stem cells (HSCs) are commonly used for curing malignant and nonmalignant hematopoiesis disorders. In recent years, HSC potential giving rise to multilineage progeny has been reported. This issue, together with their availability and number, has made them ideal candidates for β-cell replacement in diabetic patients. HSC capacity to differentiate to insulin-producing cells has been at the center of debate for the past 5 years and it now seems that their role could more likely be that of helper cells able to facilitate survival or stimulate proliferation of endogenous β cells. In addition, clinical studies are ongoing about the possible use of HSCs to stop autoimmune destruction at the onset of diabetes or to induce tolerance through microchimerism in pancreatic islet transplantation.

Original languageEnglish
Pages (from-to)119-124
Number of pages6
JournalCurrent Diabetes Reports
Volume9
Issue number2
DOIs
Publication statusPublished - 2009

Fingerprint

Hematopoietic Stem Cells
Stem Cells
Islets of Langerhans Transplantation
Chimerism
Hematopoiesis
Helper-Inducer T-Lymphocytes
Cell Proliferation
Insulin
Survival

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Internal Medicine

Cite this

The contribution of hematopoietic stem cells to beta-cell replacement. / Sordi, Valeria; Piemonti, Lorenzo.

In: Current Diabetes Reports, Vol. 9, No. 2, 2009, p. 119-124.

Research output: Contribution to journalArticle

@article{dd769f65446e4bf596facb2ddcae0615,
title = "The contribution of hematopoietic stem cells to beta-cell replacement",
abstract = "Hemopoietic stem cells (HSCs) are commonly used for curing malignant and nonmalignant hematopoiesis disorders. In recent years, HSC potential giving rise to multilineage progeny has been reported. This issue, together with their availability and number, has made them ideal candidates for β-cell replacement in diabetic patients. HSC capacity to differentiate to insulin-producing cells has been at the center of debate for the past 5 years and it now seems that their role could more likely be that of helper cells able to facilitate survival or stimulate proliferation of endogenous β cells. In addition, clinical studies are ongoing about the possible use of HSCs to stop autoimmune destruction at the onset of diabetes or to induce tolerance through microchimerism in pancreatic islet transplantation.",
author = "Valeria Sordi and Lorenzo Piemonti",
year = "2009",
doi = "10.1007/s11892-009-0021-x",
language = "English",
volume = "9",
pages = "119--124",
journal = "Current Diabetes Reports",
issn = "1534-4827",
publisher = "Current Medicine Group",
number = "2",

}

TY - JOUR

T1 - The contribution of hematopoietic stem cells to beta-cell replacement

AU - Sordi, Valeria

AU - Piemonti, Lorenzo

PY - 2009

Y1 - 2009

N2 - Hemopoietic stem cells (HSCs) are commonly used for curing malignant and nonmalignant hematopoiesis disorders. In recent years, HSC potential giving rise to multilineage progeny has been reported. This issue, together with their availability and number, has made them ideal candidates for β-cell replacement in diabetic patients. HSC capacity to differentiate to insulin-producing cells has been at the center of debate for the past 5 years and it now seems that their role could more likely be that of helper cells able to facilitate survival or stimulate proliferation of endogenous β cells. In addition, clinical studies are ongoing about the possible use of HSCs to stop autoimmune destruction at the onset of diabetes or to induce tolerance through microchimerism in pancreatic islet transplantation.

AB - Hemopoietic stem cells (HSCs) are commonly used for curing malignant and nonmalignant hematopoiesis disorders. In recent years, HSC potential giving rise to multilineage progeny has been reported. This issue, together with their availability and number, has made them ideal candidates for β-cell replacement in diabetic patients. HSC capacity to differentiate to insulin-producing cells has been at the center of debate for the past 5 years and it now seems that their role could more likely be that of helper cells able to facilitate survival or stimulate proliferation of endogenous β cells. In addition, clinical studies are ongoing about the possible use of HSCs to stop autoimmune destruction at the onset of diabetes or to induce tolerance through microchimerism in pancreatic islet transplantation.

UR - http://www.scopus.com/inward/record.url?scp=63349101763&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=63349101763&partnerID=8YFLogxK

U2 - 10.1007/s11892-009-0021-x

DO - 10.1007/s11892-009-0021-x

M3 - Article

C2 - 19323956

AN - SCOPUS:63349101763

VL - 9

SP - 119

EP - 124

JO - Current Diabetes Reports

JF - Current Diabetes Reports

SN - 1534-4827

IS - 2

ER -